VODG - Vitro Diagnostics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1650
0.0000 (0.00%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close0.1650
Open0.1650
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1650 - 0.1650
52 Week Range0.0300 - 0.4500
Volume7,000
Avg. Volume6,445
Market Cap3.98M
Beta (3Y Monthly)3.18
PE Ratio (TTM)N/A
EPS (TTM)-0.0210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE16 days ago

    Vitro Biopharma Obtains CLIA Certification Complimenting its Ongoing Stem Cell Clinical Trials

    GOLDEN, CO / ACCESSWIRE / April 2, 2019 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma announced receipt of a Certificate of Compliance with CLIA (Clinical Laboratory Improvement Amendment) ...

  • ACCESSWIRE27 days ago

    Vitro Biopharma 1st Quarter ended January 31st 2019 Financial Results of Operations

    GOLDEN, CO / ACCESSWIRE / March 22, 2019 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st 2019 financial results of operations. Vitro Diagnostics Inc. (''Vitro Biopharma'') is pleased to announce a record 1st quarter in Stem Cell Revenues. Vitro Biopharma recorded 1st quarter revenues of $192,895 vs $87,185, an increase of 121% over the same comparative quarter last year.

  • ACCESSWIRE3 months ago

    Vitro Biopharma 2018 CEO Shareholder Letter: Record Revenues from Stem Cell Treatments

    GOLDEN, CO / ACCESSWIRE / January 24, 2019 / VitroDiagnostics, Inc. (VODG), dba Vitro Biopharma, announced its CEO letter to its shareholders including discussion of its 2018 results of operations ended October 31st 2018 and its expansion plans for 2019. Increased allogeneic MSC stem cell therapy sales drove revenue in our Cayman Island and New Zealand clinical trials. Launched a stem cell based cosmetic device for topical use only through a partnership with Jack Zamora MD, a Denver-based cosmetic surgeon.

  • ACCESSWIRE4 months ago

    Vitro Biopharma Receives ISO 9001 Certification

    GOLDEN, CO / ACCESSWIRE / December 11, 2018 / VitroDiagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma (''Vitro'') one of theworld's emerging biotechnology companies focused on Umbilical Cord MesenchymalStem ...

  • ACCESSWIRE6 months ago

    Vitro BioPharma Engages Senior Director of Sales and Marketing

    GOLDEN, CO / ACCESSWIRE / October 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, today announced the engagement of a senior Sales and Marketing Director. The company has engaged Keith V. Burge to be its full time Director of Sale and Marketing. Mr. Burge has a B.S. in biology and has extensive experience in building sales channels and providing market branding for new products going to market.

  • ACCESSWIRE7 months ago

    Vitro Biopharma 3rd Quarter 2018 Financial Results of Operations and Shareholder Letter

    GOLDEN, CO / ACCESSWIRE / September 24, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma , announced its 3rd quarter financial results of operations, ended July 31 st , 2018. Vitro ...

  • ACCESSWIRE10 months ago

    Vitro Bio-Pharma 2nd Quarter Ended April 30th 2018 Financial Results of Operations

    GOLDEN, CO / ACCESSWIRE / June 26, 2018 / Vitro Diagnostics, Inc. (VODG), dba Vitro BioPharma, announced its 2nd quarter ended April 30th 2018 financial results of operations. Vitro Diagnostics Inc. (''Vitro'') is pleased to announce a record 2nd quarter in Stem Cell Revenues. Vitro recorded 2nd quarter revenues of $125,886 vs $56,633 an increase of 222% over the same comparative quarter last year.

  • ACCESSWIRE11 months ago

    Vitro Bio-Pharma Debt Re-Capitalization and Executive Team Formation

    GOLDEN, CO / ACCESSWIRE / May 3, 2018 / Vitro Diagnostics, Inc. (VODG), dba Vitro BioPharma, announced today the details of its balance sheet re-capitalization and the formation of its executive team effective April 30th 2018. The company reorganized $1,003,119 of the company's founder and C.E.O. advances to the company that were advanced during the Research and Development years of the company over the last ten plus years. As previously announced the company has entered into the commercialization of its Stem Cell Therapies and is growing the companies operating business with new Stem Cell clinics, physicians and patients.